Lung-MAP Poster
Lung-MAP Update
October 25, 2017
S1400, known as Lung-MAP, has registered 1,400 patients.
This marks a major milestone for SWOG's precision medicine trial. Launched in 2014, Lung-MAP is the National Cancer Institute's first precision medicine trial, and is testing new biomarker driven therapies as well as immunotherapy and immunotherapy combinations for patients with advanced squamous cell lung cancer. The trial, managed by SWOG, is a partnership that includes the NCI, Friends of Cancer Research, and the Foundation for the National Institutes of Health. Learn more at www.lung-map.org.
Other Recent Stories
Mar 28, 2025
27 editions of our flagship training course = huge impact
Mar 21, 2025
The S2212 de-escalation trial asks important questions the NCI's NCTN is uniquely qualified to answer
Mar 19, 2025
GU investigator Dr. Parminder Singh leads second team to tackle the Tour de Scottsdale.